Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

DW34

😃Good
Catalog No. T210782Cas No. 2758171-54-7

DW34 is an orally bioactive pan-BRD4-D1-biased inhibitor that also exhibits BRD4-D2 activity. It demonstrates a low nanomolar inhibitory effect comparable to I-BET151 (EC50 value of 0.16 μM), with an EC50 value of 0.14 μM. DW34 significantly alleviates lipopolysaccharide (LPS)-induced liver inflammation and acetaminophen (APAP)-induced toxicity by reducing chemokine expression and cell necrosis.

DW34

DW34

😃Good
Catalog No. T210782Cas No. 2758171-54-7
DW34 is an orally bioactive pan-BRD4-D1-biased inhibitor that also exhibits BRD4-D2 activity. It demonstrates a low nanomolar inhibitory effect comparable to I-BET151 (EC50 value of 0.16 μM), with an EC50 value of 0.14 μM. DW34 significantly alleviates lipopolysaccharide (LPS)-induced liver inflammation and acetaminophen (APAP)-induced toxicity by reducing chemokine expression and cell necrosis.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
10 mgInquiry10-14 weeks10-14 weeks
50 mgInquiry10-14 weeks10-14 weeks
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
DW34 is an orally bioactive pan-BRD4-D1-biased inhibitor that also exhibits BRD4-D2 activity. It demonstrates a low nanomolar inhibitory effect comparable to I-BET151 (EC50 value of 0.16 μM), with an EC50 value of 0.14 μM. DW34 significantly alleviates lipopolysaccharide (LPS)-induced liver inflammation and acetaminophen (APAP)-induced toxicity by reducing chemokine expression and cell necrosis.
In vitro
DW34 (Compound 3) effectively inhibits the expression of CXCL1 and CCL2 in LPS-induced transformed sinusoidal endothelial cells (TSECs) at concentrations of 0.31-5 μM over 5 hours. At 0.5-5 μM over 2 hours, DW34 demonstrates a stabilization effect on BRD4 in HEK293T cells comparable to I-BET151. Furthermore, DW34 exhibits good tolerance in transformed sinusoidal endothelial cells (TSECs) at concentrations ranging from 0.1 to 200 μM over 4 hours. It also induces a toxic response in megakaryocytes with an EC50 value of 90 nM.
In vivo
When administered orally at 30 mg/kg for durations of 9 or 12 hours, DW34 effectively reduces LPS-induced liver inflammation and APAP-induced toxicity by decreasing chemokine expression and cellular necrosis.
Chemical Properties
Molecular Weight434.58
FormulaC25H34N6O
Cas No.2758171-54-7
SmilesN1=NN(C(C=2N=C(OC=3C=C(C=C(C3)C)C)C=CC2)=C1C)C4CCN(CCN(C)C)CC4
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy DW34 | purchase DW34 | DW34 cost | order DW34 | DW34 chemical structure | DW34 in vivo | DW34 in vitro | DW34 formula | DW34 molecular weight
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.